Fidelity SPDR Advertisement
Home > Boards > US Listed > Biotechs > Rock Creek Pharmaceuticals Inc. (RCPI)

The Latest Short Interest Report...

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (1) | Next 10 | Previous | Next
NukeJohn Member Profile
 
Followed By 79
Posts 1,984
Boards Moderated 1
Alias Born 11/12/03
160x600 placeholder
Current Report Filing (8-k) "Edgar (US Regulatory)" - 9/24/2014 8:31:05 AM
Rock Creek Pharmaceuticals Receives New Dietary Ingredient Notification (NDIN) Response "PR Newswire (US)" - 9/12/2014 8:30:00 AM
Initial Statement of Beneficial Ownership (3) "Edgar (US Regulatory)" - 8/27/2014 4:23:53 PM
Initial Statement of Beneficial Ownership (3) "Edgar (US Regulatory)" - 8/22/2014 4:07:54 PM
Small Company Offering and Sale of Securities Without Registration (d) "Edgar (US Regulatory)" - 8/22/2014 4:00:28 PM
Amended Quarterly Report (10-q/a) "Edgar (US Regulatory)" - 8/18/2014 4:31:06 PM
Quarterly Report (10-q) "Edgar (US Regulatory)" - 8/11/2014 5:12:27 PM
Rock Creek Pharmaceuticals Reports Second Quarter and Announces Clinical Update "PR Newswire (US)" - 8/11/2014 4:20:00 PM
Current Report Filing (8-k) "Edgar (US Regulatory)" - 8/6/2014 4:38:09 PM
Rock Creek Pharmaceuticals Expands The Board with the Appointment of Two Independent Directors "PR Newswire (US)" - 8/6/2014 1:04:00 PM
Rock Creek Pharmaceuticals to Present at the Annual BioPharm America International Partnering Conference "PR Newswire (US)" - 8/4/2014 2:49:00 PM
Rock Creek Pharmaceuticals Provides Update of its European Drug Development Regulatory Strategy and selects Quotient Clinical... "PR Newswire (US)" - 7/31/2014 3:31:00 PM
Prospectus Filed Pursuant to Rule 424(b)(3) (424b3) "Edgar (US Regulatory)" - 7/16/2014 4:51:04 PM
Notice of Effectiveness (effect) "Edgar (US Regulatory)" - 7/16/2014 6:00:34 AM
Current Report Filing (8-k) "Edgar (US Regulatory)" - 7/11/2014 5:00:43 PM
Rock Creek Pharmaceuticals Issues Update On US Investigational New Drug Application "PR Newswire (US)" - 7/11/2014 4:30:00 PM
Amended Statement of Ownership (sc 13g/a) "Edgar (US Regulatory)" - 7/10/2014 4:11:15 PM
Current Report Filing (8-k) "Edgar (US Regulatory)" - 7/1/2014 9:01:29 AM
Current Report Filing (8-k) "Edgar (US Regulatory)" - 6/2/2014 5:09:24 PM
Star Scientific Announces Corporate Name Change to Rock Creek Pharmaceuticals "PR Newswire (US)" - 6/2/2014 4:58:00 PM
Current Report Filing (8-k) "Edgar (US Regulatory)" - 5/23/2014 4:56:14 PM
Quarterly Report (10-q) "Edgar (US Regulatory)" - 5/12/2014 4:53:00 PM
Current Report Filing (8-k) "Edgar (US Regulatory)" - 5/2/2014 4:52:40 PM
Amended Annual Report (10-k/a) "Edgar (US Regulatory)" - 4/30/2014 4:51:49 PM
Star Scientific Retains Shareholder Intelligence Services, LLC "PR Newswire (US)" - 4/30/2014 2:00:00 PM
NukeJohn   Thursday, 10/04/12 10:10:26 PM
Re: None
Post # of 20826 
The Latest Short Interest Report...


had over 26 million shares short and >23 days to cover....and that's just the reported short interest.

What if Anatabine Citrate really does stop autoimmune thyroiditis in its tracks? What if it really does counter the chronic low grade inflammation that appears to be caused by NF-kB getting out of control?

FWIW, Chronic Inflammation appears to be involved in at least seven of the top ten causes of death in the US.

http://www.lef.org/protocols/health_concerns/chronic_inflammation_01.htm

excerpts...

Chronic Inflammation

Of the ten leading causes of mortality in the United States, chronic, low-level inflammation contributes to the pathogenesis of at least seven. These include heart disease, cancer, chronic lower respiratory disease, stroke, Alzheimer’s disease, diabetes, and nephritis (Centers for Disease Control and Prevention 2011; Bastard et al. 2006; Cao 2011, Jha et al. 2009; Ferrucci et al. 2010; Glorieux et al. 2009; Kundu et al. 2008; Murphy 2012; Singh et al. 2011).

Inflammation has classically been viewed as an acute (short term) response to tissue injury that produces characteristic symptoms and usually resolves spontaneously. More contemporary revelations show chronic inflammation to be a major factor in the development of degenerative disease and loss of youthful functions.

Chronic inflammation can be triggered by cellular stress and dysfunction, such as that caused by excessive calorie consumption, elevated blood sugar levels, and oxidative stress. It is now clear that the destructive capacity of chronic inflammation is unprecedented among physiologic processes (Karin et al. 2006).

The danger of chronic, low-level inflammation is that its silent nature belies its destructive power.

In fact, stress-induced inflammation, once triggered, can persist undetected for years, or even decades, propagating cell death throughout the body. Due to the fact that it contributes so greatly to deterioration associated with the aging process, this silent state of chronic inflammation has been coined “inflammaging”.


Chronic low-level inflammation may be threatening your health at this very moment, without you realizing it. In this protocol you will learn about low-cost blood tests that can assess the inflammatory state within your body. You’ll also discover novel approaches that combat chronic inflammation to help avoid age-related health decline.



-------------------------------------------------------
For Example...

Here's a Cardiology paper worth reading.

http://content.onlinejacc.org/article.aspx?articleid=1188627

While I am a layman when it comes to medicine, I do have a scientific background. My take on the above article is:

1. Elevated CRP levels are definitely linked to heart disease. The higher the CRP levels are, the greater the risk.

2. We already know that activation NF-kB causes increases the production of pro inflammatory cytokines, which in turn causes an increase in CRP levels. But, it also appears that an increase in the CRP levels increase the transcription of NF-kB. Therefore, it becomes a never ending cycle of chronic low grade inflammation.

What if a company discovered something that stopped the transcription of NF-kB and ended that vicious cycle of chronic low grade inflammation in the body? If it really stopped the transcription of NF-kB, and therefore stopped that low level chronic inflammation process....but it did not interfere with the normal inflammation process your body needs to fight off diseases and infections, how much would that be worth? Put another way, if something was available that significantly reduced the mortality rate associated with heart disease, cancer, chronic lower respiratory disease, stroke, Alzheimer’s disease, diabetes...etc......how much would that be worth?

Well, IMHO, it is worth a small fortune and it is already available off the shelf in most cities in the US. It is called Anatabloc and it is from Rock Creek Pharmaceuticals, a division of Star Scientific (STSI).

How do I know that Anatabloc stops that chronic low grade inflammation, yet does not interfere with the body's normal immune response processes? It's simple. I have been taking Anatabloc for over a year. Since I have RA (and bronchial asthma), I have frequent blood tests that include CRP levels due to my RA prescription drugs. Even though my use of Anatabloc has helped me to stop taking most of my prescription medications (including Methrotrexate), my CRP levels have still consistently been <.5, except for one time about 5 months ago when it was over 3. I had a blood test on a Friday back in May and my CRP level was 3.2. Coincidentally, I wasn't feeling very good when I went in to have my blood drawn, and that night I came down with the flu and was bedridden the whole weekend. I had the full suite of symptoms (nausea, vomiting, fever, chills, body aches and pains)....but they were completely gone in about 2 days. The point I am making is that my CRP levels did in fact rise during the early stages of my illness...so the fact I took Anatabloc (which I continued throughout the duration), did not keep my body from fighting the infection. In fact, I think it shortened the duration of my flu when compared to most people.

Star Scientific has discovered something that I think will change healthcare in the US and around the world. One day soon, every major pharmaceutical company will beat a path to their door.

IMHO, we should not be focusing on Star's tobacco litigation. The focus should be on Star's discovery of Anatabine Citrate. As investors, we should be investigating the various problems caused by NF-kB in the human body, and how Anatabloc alleviates those problems. IMHO, the tobacco industry will eventually have to pay Star for their valid tobacco patents. At some point, the settlement arrangement with RJR will become known. IMHO, Star will eventually be paid by all the tobacco companies (including Philip Morris).

There is only one analyst that covers Star Scientific (Otis Bradley of Gilford Securities)...and he gets it. IMHO, the longer the other big tobacco companies fight, the more they will have to pay (and ultimately the higher the stock will go). For more information read Otis Bradley's report initiating coverage, see the link below.

http://www.wirelessledger.com/Gilford_initiates_CIGX_08_01_2012.pdf

JMHO,

NJ



Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (1) | Next 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist